Abstract

The very impressive scientific developments in the biomedical sciences which have occurred in recent years provide the prospect of new, more effective vaccines against those communicable diseases for which at present there are either no vaccines or for which existing vaccines are less than satisfactory. These developments include identification of protective antigens by the use of monoclonal antibody techniques and their production by recombinant DNA technology and peptide synthesis. In addition, there is much new information on the functioning of the immune system which provides a basis for rational vaccine design. In October 1983, WHO held a meeting on New Approaches to Vaccine Development. The meeting was attended by eminent scientists in microbiology, immunology, biochemistry, vaccine production and vaccine control. A major recommendation of the meeting to WHO was for the Organization to establish with urgency a programme for vaccine development. The Organization responded positively to this recommendation, agreeing that the gathering momentum of biotechnological research provided WHO with the opportunity to play a crucial role in encouraging, coordinating and developing priorities on new vaccines so that the great potential of recent progress was harnessed for the maximum benefit of all countries. WHO could take advantage of its unique position of being deeply involved in all problems of communicable diseases in the developing world and having at the same time knowledge of scientific achievements in the most privileged countries. The same general view was expressed by the WHO Advisory Committee on Medical Research at its October 1983 session. Since the development of vaccines in most areas is intimately related to the development of diagnostic tools (including reagents), such activities, when appropriate, are considered as part of the Programme. Mankind is now on the threshold of a new era in the technology of vaccine development and production and it behoves WHO to take the leadership in this endeavour.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.